U.S. Imposes 100% Section 232 Tariffs on Patented Pharmaceuticals and Ingredients
New U.S. Section 232 pharmaceutical tariffs introduce a 100% duty on patented drugs and APIs beginning in 2026, with tiered rates tied to onshoring and pricing agreements. While generics and specialty medicines remain exempt, companies can reduce tariffs to 0% through MFN pricing and domestic manufacturing commitments, signaling a major shift in global pharmaceutical supply chains and U.S. trade policy.